Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Colorectal Neoplasms 49Rectal Neoplasms 29Pancreatic Neoplasms 25Colonic Neoplasms 25Neoplasm Metastasis 19Stomach Neoplasms 17Neoplasms 17Esophageal Neoplasms 17Head and Neck Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Breast Neoplasms 10Adenocarcinoma Of Esophagus 8Esophageal Squamous Cell Carcinoma 6Cholangiocarcinoma 6Carcinoma, Squamous Cell 6Gallbladder Neoplasms 5Carcinoma, Hepatocellular 5Bile Duct Neoplasms 5Liver Neoplasms 4Anus Neoplasms 4Lung Neoplasms 3Triple Negative Breast Neoplasms 2Somatostatinoma 2Sarcoma 2Peritoneal Neoplasms 2Mouth Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

Doxorubicin 13Gemcitabine 10Cyclophosphamide 10pazopanib 8Filgrastim 8Radiotherapy 7Ifosfamide 7Cisplatin 7Irinotecan 6Docetaxel 6Radiation 5Granulocyte Colony-Stimulating Factor 5Etoposide 5Trabectedin 4Magnetic Resonance Spectroscopy 4Celecoxib 4Busulfan 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3sargramostim 3pembrolizumab 3X-Rays 3Sirolimus 3Radiotherapy, Intensity-Modulated 3Paclitaxel 3Neoadjuvant Therapy 3Leucovorin 3Dexrazoxane 3Cryosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Sarcoma × Fluorouracil × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT03009058 2024-11-25

MODULATE

Immodulon Therapeutics Ltd

Phase 1/2 Terminated
2 enrolled 7 charts
DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡